Compounds > dibromsalan
Page last updated: 2024-11-05

dibromsalan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Dibromsalan, also known as 3,5-dibromo-N-(trichloromethylthio)salicylamide, is an organobromine compound. It is a broad-spectrum antibacterial agent that has been used in the past as an antiseptic and disinfectant. Dibromsalan is effective against a wide range of bacteria, including Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. However, due to concerns about its potential toxicity, dibromsalan is no longer used in many countries. It is important to note that Dibromsalan is not approved for human use in the United States. Research on Dibromsalan focuses on its environmental fate and transport, as well as its potential for bioaccumulation. This compound is studied to understand its potential impact on human health and the environment. Dibromsalan has been shown to bioaccumulate in organisms, which could pose risks to both humans and wildlife. The synthesis of Dibromsalan involves a reaction between 3,5-dibromosalicylic acid and trichloromethanesulfenyl chloride.'

Cross-References

ID SourceID
PubMed CID14839
CHEMBL ID21869
SCHEMBL ID646973
MeSH IDM0050453

Synonyms (51)

Synonym
nsc 20527
dibromsalanum [inn-latin]
brn 1125597
salicylanilide, 4',5-dibromo-
epa pesticide chemical code 077402
dibromsalan [usan:inn]
p-bromanilid kyseliny 5-bromsalicylove [czech]
caswell no. 287c
dibronsalan [inn-spanish]
einecs 201-724-1
wr 52606
dibromsalan (usan)
D03780
component of asc-4
disanyl
4',5-dibromosalicylanilide
87-12-7
wln: qr de bvmr de
component of diaphene
5-bromosalicylic acid p-bromoanilide
nsc-20527
dibromsalen
bromsalicylanilide
component of temasept i
salicylanilide,5-dibromo-
benzamide, 5-bromo-n-(4-bromophenyl)-2-hydroxy-
5-bromosalicyl-4-bromoanilide
3-bromo-6-hydroxybenz-p-bromanilide
dibromsalan
dibask
temasept
nsc20527
bromosalicylanilide
nsc81947
nsc-81947
5-bromo-n-(4-bromophenyl)-2-hydroxy-benzamide
CHEMBL21869
5-bromo-n-(4-bromophenyl)-2-hydroxybenzamide
p-bromanilid kyseliny 5-bromsalicylove
dibronsalan
unii-n9900k2rbt
n9900k2rbt ,
dibromsalanum
dibromsalan [usan]
dibromsalan [mart.]
dibromsalan [who-dd]
dibromsalan [inn]
SCHEMBL646973
DTXSID1041500
Q27284731
Z68085475
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1339417Antimycobacterial activity against Mycobacterium avium My 330/80 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID18964Observed inhibitory activity against various Actinomycetes strains1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus.
AID1339420Antimycobacterial activity against Mycobacterium kansasii isolate 235/80 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339418Antimycobacterial activity against Mycobacterium avium My 330/80 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339424Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID19264Partition coefficient is determined in octanol/buffer solution1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus.
AID1339423Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339416Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID25563Dissociation constant is the negative logarithm of the equilibrium coefficient of the neutral and charged forms of the compound1981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus.
AID18966Distribution coefficient between octanol and aqueous phase at pH7.21981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus.
AID1339419Antimycobacterial activity against Mycobacterium kansasii isolate 235/80 after 7 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339422Antimycobacterial activity against Mycobacterium kansasii isolate 6509/96 after 7 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339421Antimycobacterial activity against Mycobacterium kansasii isolate 235/80 after 21 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID30576In vitro antibacterial activity against Actinomyces viscosus M-100-20001981Journal of medicinal chemistry, Oct, Volume: 24, Issue:10
Potential salicylamide antiplaque agents: in vitro antibacterial activity against Actinomyces viscosus.
AID1339425Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by MTS assay2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339415Antimycobacterial activity against Mycobacterium tuberculosis H37Rv My 331/88 after 14 days by micromethod2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
AID1339426Selectivity index, ratio of IC50 for human HepG2 cells to MIC for Mycobacterium tuberculosis H37Rv after 21 days2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (83.33)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.01 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chlorpromazine
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.		1.9510organochlorine compound;
phenothiazines;
tertiary amine		anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.1510carbohydrazideantitubercular agent;
drug allergen
aminosalicylic acid
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.		2.1510aminobenzoic acid;
phenols		antitubercular agent
salicylanilide
salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.		1.9310benzanilide fungicide;
salicylamides;
salicylanilides
3,3',4',5-tetrachlorosalicylanilide
3,3',4',5-tetrachlorosalicylanilide : A salicylanilide derivative with chloride substituents at C-3 and C-5 of the salicylate moiety and at C-3 and C-4 of the anilide moiety.		1.9510dichlorobenzene;
salicylanilides		drug allergen
tribromsalan
tribromsalan: germicide; structure. tribromosalicylanilide : A salicylanilide derivative with bromo- substituents at C-3 and C-5 of the salicylate moiety and at C-4 of the anilide moiety.		2.6530salicylanilides
fluorophene
[no description available]		1.9610benzamides
parbendazole
parbendazole: anthelmintic used against a variety of gastrointestinal parasites; minor descriptor (75-86); on-line & INDEX MEDICUS search BENZIMIDAZOLES; RN given refers to parent cpd		1.9610benzimidazoles;
carbamate ester
4'-bromosalicylanilide
4'-bromosalicylanilide: photoproduct from UV-irradiation of tribromsalan; structure		1.9610
imd 0354
N-(3,5-bis(trifluoromethyl)phenyl)-5-chloro-2-hydroxybenzamide: a cardioprotective agent that inhibits IkappaB kinase beta (IKKbeta); structure in first source		2.1510benzamides
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		1.9510benzenes;
hydroxycoumarin;
methyl ketone
ConditionIndicatedRelationship StrengthStudiesTrials
Dental Plaque
A film that attaches to teeth, often causing DENTAL CARIES and GINGIVITIS. It is composed of MUCINS, secreted from salivary glands, and microorganisms.		01.9610
Tuberculosis, Drug-Resistant
[description not available]		02.1510
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.1510
Fasciola Infection
[description not available]		01.9610
Ovine Diseases
[description not available]		01.9610
Fascioliasis
Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.		01.9610
Actinic Reticuloid Syndrome
[description not available]		01.9510